DBV Technologies: FDA Submission for Viaskin Peanut Scheduled for Q3 2026
DBV Technologies has announced the completion of its extensive discussions with the Food and Drug Administration (FDA) regarding the submission of a Biologics License Application (BLA) for its Viaskin Peanut patch for children aged 4 to 7 with peanut allergies. With no additional data requested by the Agency, the French biotech plans to submit the application in the third quarter of 2026.
Structured Exchanges Without Additional Data Requests
DBV conducted structured discussions with the FDA to ensure a comprehensive and efficient review of the upcoming BLA. During these discussions, the U.S. federal agency provided specific feedback on the organization, structuring, and formatting of existing data, particularly regarding Chemical, Manufacturing, and Controls (CMC) elements and biostatistical aspects. The FDA did not request additional data, which is a positive sign for the progression of the application. CEO Daniel Tassé emphasized that the Viaskin Peanut patch remains an innovative and complex product for which there is no regulatory precedent, justifying the thorough nature of these preliminary exchanges.
Submission Planned for the Third Quarter of 2026
DBV plans to take the necessary time to integrate all comments from the FDA before submitting the BLA during the third quarter of 2026. This approach is part of a constructive collaboration with the Agency, similar to the exchanges that typically occur after the official submission of a biologics license application. The biotech is organizing a conference call with investors on the same day, June 29 at 5 PM (Eastern Time), to discuss this regulatory progress and answer questions related to the product's trajectory.
